Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

This trial is comparing two treatment sequencing strategies — giving chemotherapy/immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) — for patients with locally advanced recurrent nasopharyngeal carcinoma (NPC), a cancer at the back of the nose. **You may be eligible if...** - You have been diagnosed with recurrent nasopharyngeal carcinoma that has come back - Your cancer is surgically removable and has not spread to distant organs - You are 18 to 75 years old and in good enough health for surgery, chemotherapy, and immunotherapy - It has been at least 6 months since your previous radiation treatment finished, and you only had one prior course of radiation **You may NOT be eligible if...** - You have another cancer (diagnosed within the past 5 years) - You have a serious autoimmune disease or are taking high-dose steroids - You received radioactive particle implants previously - You have a live vaccine within 4 weeks of starting treatment Talk to your doctor to see if this trial is right for you.